ERT Announces Appointment of New President and CEO
ERT announced that its Board of Directors has appointed Jeffrey S. Litwin, M.D. its new President and Chief Executive Officer and as a member of the board.
Dr. Litwin joined ERT in 2000 as Senior Vice President and Chief Medical Officer and was subsequently promoted in December 2005 to Executive Vice President and Chief Medical Officer. Dr. Litwin oversaw ERT's global cardiac safety operations for seven years and was instrumental in implementing EXPERT, ERT's digital operating system. During this time period, ERT experienced tremendous growth with revenues increasing more than three-fold. For the last four years, he has been responsible for leading ERT's consulting business, assisting over 150 companies with the design and evaluation of cardiac safety testing programs. Throughout his career at ERT, Dr. Litwin has also been directly involved in supporting ERT's sales efforts.
In addition to his responsibilities at ERT, Dr. Litwin serves on the DIA Annual Meeting planning committee, the Applied Clinical Trials Editorial Board, and the Board of Directors of the Metrics Champion Consortium. Dr. Litwin is a board-certified cardiologist and left his cardiology practice to serve as Director, Medical Affairs, Wyeth-Ayerst Laboratories from 1988 to 1990 where he had responsibility for medical services, Phase IV research, and pharmacovigilance for all marketed cardiac safety products. From 1990 to 1993, Dr. Litwin served as Deputy Medical Director of Nutri/System Inc., and from 1993 until joining ERT, Dr. Litwin served as Executive Vice President and Chief Operating Officer of Executive Health Group, the nation's leading provider of executive physical examinations. In that role, he built a worldwide network of over 1000 physician offices to provide pre-employment physicals and high quality physical examinations to corporate executives.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.